PRU offer is clearly better for shareholder.Not clear why Board is still in bed with the Chinese on this.Cash burn while this project is spinning wheels is concerning.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%